Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2016, Article ID 6216128, 3 pages
http://dx.doi.org/10.1155/2016/6216128
Case Report

Listeria Rhombencephalitis Complicating Anti-TNF Treatment during an Acute Flare of Crohn’s Colitis

1Belfast City Hospital, Lisburn Road, Belfast, UK
2Ulster Hospital Dundonald, Upper Newtownards Road, Belfast, UK

Received 2 May 2016; Revised 2 August 2016; Accepted 9 August 2016

Academic Editor: Özlem Yönem

Copyright © 2016 L. Stratton and G. R. Caddy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Institute for Health and Clinical Excellence, Crohn's Disease: Management, NICE Guideline (CG152), 2012.
  2. J. F. Rahier, F. Magro, C. Abreu et al., “Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 8, no. 6, pp. 443–468, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. J. How, “Are nectarines to blame? A case report and literature review of spontaneous bacterial peritonitis due to Listeria monocytogenes,” Connecticut Medicine, vol. 79, no. 1, pp. 31–36, 2015. View at Google Scholar
  4. S. Barocci, A. Mancini, B. Canovari et al., “Listeria monocytogenes meningitis in an immunocompromised patient,” New Microbiologica, vol. 38, no. 1, pp. 113–118, 2015. View at Google Scholar · View at Scopus
  5. S. Lomonaco, D. Nucera, and V. Filipello, “The evolution and epidemiology of Listeria monocytogenes in Europe and the United States,” Infection, Genetics and Evolution, vol. 35, pp. 172–183, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Goulet, L. A. King, V. Vaillant, and H. de Valk, “What is the incubation period for listeriosis?” BMC Infectious Diseases, vol. 13, no. 1, pp. 11–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Kelesidis, A. Salhotra, J. Fleisher, and D. Z. Uslan, “Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?” Journal of Infection, vol. 60, no. 5, pp. 386–396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Pelegrín, M. Moragas, C. Suárez et al., “Listeria monocytogenes meningoencephalitis in adults: analysis of factors related to unfavourable outcome,” Infection, vol. 42, no. 5, pp. 817–827, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Bodro and D. L. Paterson, “Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?” Clinical Infectious Diseases, vol. 56, no. 11, pp. 1621–1628, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. P. McLean and R. K. Cross, “Adverse events in IBD: to stop or continue immune suppressant and biologic treatment,” Expert Review of Gastroenterology & Hepatology, vol. 8, no. 3, pp. 223–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Toruner, E. V. Loftus Jr., W. S. Harmsen et al., “Risk factors for opportunistic infections in patients with inflammatory bowel disease,” Gastroenterology, vol. 134, no. 4, pp. 929–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Ali, S. Kaitha, S. Mahmood, A. Ftesi, J. Stone, and M. S. Bronze, “Clinical use of anti-TNF therapy and increased risk of infections,” Journal of Drug, Healthcare and Patient Safet, vol. 5, pp. 79–99, 2013. View at Google Scholar